BISPHOSPHONATES: EVALUATION OF THE DENTISTRY KNOWLEDGE
DOI:
https://doi.org/10.47820/recima21.v3i8.1846Keywords:
Bisphosphonates, Osteonecrosis of the jaws;, DiagnosticsAbstract
Bisphosphonates (BFs) are drugs used widely in medicine, especially in the areas of cancer treatment and osteoporosis and other bone diseases. They act by inhibiting osteoclastic activity, thus altering all bone remodeling; these accumulate in the bone and can cause necrosis. Bisphosphonate-related osteonecrosis lesions of the jaws are usually preceded by dental treatment, so it is a fundamental role of the dental surgeon (DC) to diagnose and treat these pathologies, and especially to prevent them. In this way, negligence within an anamnesis in relation to this medication should be avoided, thus reducing the risks of major mutilations and loss of quality of life for the patient. This study aims to evaluate the level of knowledge of dentists regarding bisphosphonates.
Downloads
References
MARX, R. E. et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis)
of the jaws: Risk factors, recognition, prevention, and treatment. Journal of Oral and Maxillofacial Surgery, v. 63, n. 11, p. 1567–1575, 2005.
MAVROKOKKI, T. et al. Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia. Journal of Oral and Maxillofacial Surgery, v. 65, n. 3, p. 415–423, 2007.
EDWARDS, B. J. et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association (1939), v. 139, n. 12, p. 1674–1677, 2008.
LO, J. C. et al. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. Journal of Oral and Maxillofacial Surgery, v. 68, n. 2, p. 243–253, 2010.
BARASCH, A. et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. Journal of dental research, v. 90, n. 4, p. 439–44, 2011.
DINIZ-FREITAS, M. et al. Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain. Medicina Oral, Patologia Oral y Cirugia Bucal, v. 17, n. 5, 2012.
GÓMEZ-MORENO, G. et al. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: A case report solved with non-invasive treatment. European Review for Medical and Pharmacological Sciences, v. 18, n. 9, p. 1391–1397, 2014.
TARDAST, A. et al. Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking. Journal of applied oral science : revista FOB, v. 23, n. 3, p. 310–4, 2015.
ROGERS, S. N. et al. United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. British Journal of Oral and Maxillofacial Surgery, v. 53, n. 2, p. 176–182, 2015.
DE LIMA, P. B. et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Supportive Care in Cancer, v. 23, n. 12, p. 3421–3426, 2015.
NISI, M. et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: A multivariate analysis. International Journal of Oral and Maxillofacial Surgery, v. 44, n. 5, p. 586–591, 2015.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
